Want to see INBS full AI Analyst Report?
INBS Stock Chart & Stats
$1.03
-$0.03(-2.02%)
At close: 4:00 PM EST
$1.03
-$0.03(-2.02%)
Day’s Range― - ―
52-Week Range$1.58 - $24.90
Previous CloseN/A
Volume32.28K
Average Volume (3M)57.68K
Market Cap
$4.71M
Enterprise Value$0.11
Total Cash (Recent Filing)$6.86M
Total Debt (Recent Filing)$1.85M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.52
Shares Outstanding2,391,846
10 Day Avg. Volume78,014
30 Day Avg. Volume57,679
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.03
Price to Sales (P/S)2.97
P/FCF Ratio-0.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-93.6
Revenue Forecast (FY)$14.65M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Revenue ModelA consumables-heavy business model creates recurring revenue and higher lifetime value per deployed reader. Durable demand for single-use cartridges in workplace, corrections and rehab settings supports predictable unit economics and amplifies scale benefits as installed base grows.
Top-line MomentumSustained TTM revenue growth signals early commercial traction and expanding adoption of the fingerprint screening system. Continued top-line momentum is essential to spread fixed costs, improve operating leverage, and move toward breakeven if sustained over multiple quarters.
FDA 510(k) Clinical Study ProgressAdvancing clinical studies for FDA 510(k) clearance is a structural catalyst: regulatory clearance would broaden U.S. market access, validate accuracy vs LC-MS/MS, and lower adoption friction among occupational health and safety buyers, strengthening long-term commercial potential.
Bears Say
Persistent Cash BurnLarge negative operating and free cash flow relative to revenue indicate the company is consuming cash to sustain operations. Unless cash generation reverses, ongoing burn necessitates external financing, which can constrain strategic execution and increase dilution risk over the medium term.
Deeply Negative MarginsSeverely negative net margin and falling gross margins point to structural cost or pricing pressure. Persistent unprofitable operations reduce reinvestment capacity, impede path to sustainable profitability, and require either meaningful scale gains or cost restructuring to correct.
Equity Volatility / Dilution RiskA fluctuating equity base and ongoing losses raise the likelihood of future equity issuance to fund operations. Recurrent dilution can erode shareholder value and limit long-term investor confidence, complicating capital planning and strategic investments.
Intelligent Bio Solutions News
INBS FAQ
What was Intelligent Bio Solutions Inc.’s price range in the past 12 months?
Intelligent Bio Solutions Inc. lowest stock price was $1.58 and its highest was $24.90 in the past 12 months.
What is Intelligent Bio Solutions Inc.’s market cap?
Intelligent Bio Solutions Inc.’s market cap is $4.71M.
When is Intelligent Bio Solutions Inc.’s upcoming earnings report date?
Intelligent Bio Solutions Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 106 days.
How were Intelligent Bio Solutions Inc.’s earnings last quarter?
Intelligent Bio Solutions Inc. released its earnings results on May 13, 2026. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Intelligent Bio Solutions Inc. overvalued?
According to Wall Street analysts Intelligent Bio Solutions Inc.’s price is currently Overvalued.
Does Intelligent Bio Solutions Inc. pay dividends?
Intelligent Bio Solutions Inc. does not currently pay dividends.
What is Intelligent Bio Solutions Inc.’s EPS estimate?
Intelligent Bio Solutions Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intelligent Bio Solutions Inc. have?
Intelligent Bio Solutions Inc. has 2,391,846 shares outstanding.
What happened to Intelligent Bio Solutions Inc.’s price movement after its last earnings report?
Intelligent Bio Solutions Inc. reported an EPS of -$1.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 25.472%.
Which hedge fund is a major shareholder of Intelligent Bio Solutions Inc.?
Currently, no hedge funds are holding shares in INBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Technical Analysis
Ownership Overview
3.78% Insiders
0.63% Mutual Funds
7.03% Other Institutional Investors
88.32% Public Companies and
Individual Investors